Assessment of inhibin and p53 in granulosa cell tumors of the ovary

John B. Gebhart, Patrick C. Roche, Gary Keeney, Timothy G. Lesnick, Karl C. Podratz

Research output: Contribution to journalArticle

37 Citations (Scopus)

Abstract

Objective. The goal of this work was to determine the cellular content of inhibin and p53 in granulosa cell tumors (GCTs). Methods. Clinical records of 47 patients (mean age, 54 years; range, 20-85 years) presenting with GCT surgically managed at our institution were abstracted. International Federation of Gynecology stage I was assigned in 39 patients, stage II in 2, and stage III in 6. Concomitant endometrial carcinoma was identified in 6 patients. Mean follow-up was 13.6 years (range, 1 day to 37.6 years). Sections from paraffin-embedded tissue blocks were analyzed immunohistochemically for expression of tissue inhibin and p53 levels. Inhibin expression was graded by intensity and reactivity, and p53, by its presence or absence. Results. The tumors of 27 patients (57%) stained strongly for inhibin intensity and showed >60% reactivity. Decreased intensity and reactivity of inhibin expression were associated with advanced- stage disease (P = 0.05 and P < 0.01, respectively, by Fisher exact test). Expression of p53 was detected in tumors from 27 patients (57%), and immunoreactivity was associated with compromised progression-free survival (P = 0.016, log-rank test). However, the association between p53 immunoreactivity and disease stage was not significant. Absence of p53 expression was significantly associated with concurrent endometrial carcinoma (P = 0.022), suggesting more molecularly intact tumors that retain functional activity. Conclusions. Although the majority of GCTs show strong expression of inhibin with regard to intensity and reactivity, weak expression is associated with advanced disease but not with decreased progression-free survival. By contrast, expression of p53 is not significantly associated with stage, but increased expression is associated with decreased disease-free survival. Absence of p53 expression appears to be associated with concurrent endometrial carcinoma. (C) 2000 Academic Press.

Original languageEnglish (US)
Pages (from-to)232-236
Number of pages5
JournalGynecologic Oncology
Volume77
Issue number2
DOIs
StatePublished - May 2000

Fingerprint

Inhibins
Granulosa Cell Tumor
Endometrial Neoplasms
Disease-Free Survival
Neoplasms
Gynecology
Paraffin
Granulosa cell tumor of the ovary

Keywords

  • Cancer stage
  • Immunohistochemistry
  • Neoplasm
  • Prognosis
  • Retrospective review

ASJC Scopus subject areas

  • Obstetrics and Gynecology
  • Oncology

Cite this

Assessment of inhibin and p53 in granulosa cell tumors of the ovary. / Gebhart, John B.; Roche, Patrick C.; Keeney, Gary; Lesnick, Timothy G.; Podratz, Karl C.

In: Gynecologic Oncology, Vol. 77, No. 2, 05.2000, p. 232-236.

Research output: Contribution to journalArticle

Gebhart, JB, Roche, PC, Keeney, G, Lesnick, TG & Podratz, KC 2000, 'Assessment of inhibin and p53 in granulosa cell tumors of the ovary', Gynecologic Oncology, vol. 77, no. 2, pp. 232-236. https://doi.org/10.1006/gyno.2000.5774
Gebhart, John B. ; Roche, Patrick C. ; Keeney, Gary ; Lesnick, Timothy G. ; Podratz, Karl C. / Assessment of inhibin and p53 in granulosa cell tumors of the ovary. In: Gynecologic Oncology. 2000 ; Vol. 77, No. 2. pp. 232-236.
@article{aacfbb9fc0fc4b588094fee54a3d88f7,
title = "Assessment of inhibin and p53 in granulosa cell tumors of the ovary",
abstract = "Objective. The goal of this work was to determine the cellular content of inhibin and p53 in granulosa cell tumors (GCTs). Methods. Clinical records of 47 patients (mean age, 54 years; range, 20-85 years) presenting with GCT surgically managed at our institution were abstracted. International Federation of Gynecology stage I was assigned in 39 patients, stage II in 2, and stage III in 6. Concomitant endometrial carcinoma was identified in 6 patients. Mean follow-up was 13.6 years (range, 1 day to 37.6 years). Sections from paraffin-embedded tissue blocks were analyzed immunohistochemically for expression of tissue inhibin and p53 levels. Inhibin expression was graded by intensity and reactivity, and p53, by its presence or absence. Results. The tumors of 27 patients (57{\%}) stained strongly for inhibin intensity and showed >60{\%} reactivity. Decreased intensity and reactivity of inhibin expression were associated with advanced- stage disease (P = 0.05 and P < 0.01, respectively, by Fisher exact test). Expression of p53 was detected in tumors from 27 patients (57{\%}), and immunoreactivity was associated with compromised progression-free survival (P = 0.016, log-rank test). However, the association between p53 immunoreactivity and disease stage was not significant. Absence of p53 expression was significantly associated with concurrent endometrial carcinoma (P = 0.022), suggesting more molecularly intact tumors that retain functional activity. Conclusions. Although the majority of GCTs show strong expression of inhibin with regard to intensity and reactivity, weak expression is associated with advanced disease but not with decreased progression-free survival. By contrast, expression of p53 is not significantly associated with stage, but increased expression is associated with decreased disease-free survival. Absence of p53 expression appears to be associated with concurrent endometrial carcinoma. (C) 2000 Academic Press.",
keywords = "Cancer stage, Immunohistochemistry, Neoplasm, Prognosis, Retrospective review",
author = "Gebhart, {John B.} and Roche, {Patrick C.} and Gary Keeney and Lesnick, {Timothy G.} and Podratz, {Karl C.}",
year = "2000",
month = "5",
doi = "10.1006/gyno.2000.5774",
language = "English (US)",
volume = "77",
pages = "232--236",
journal = "Gynecologic Oncology",
issn = "0090-8258",
publisher = "Academic Press Inc.",
number = "2",

}

TY - JOUR

T1 - Assessment of inhibin and p53 in granulosa cell tumors of the ovary

AU - Gebhart, John B.

AU - Roche, Patrick C.

AU - Keeney, Gary

AU - Lesnick, Timothy G.

AU - Podratz, Karl C.

PY - 2000/5

Y1 - 2000/5

N2 - Objective. The goal of this work was to determine the cellular content of inhibin and p53 in granulosa cell tumors (GCTs). Methods. Clinical records of 47 patients (mean age, 54 years; range, 20-85 years) presenting with GCT surgically managed at our institution were abstracted. International Federation of Gynecology stage I was assigned in 39 patients, stage II in 2, and stage III in 6. Concomitant endometrial carcinoma was identified in 6 patients. Mean follow-up was 13.6 years (range, 1 day to 37.6 years). Sections from paraffin-embedded tissue blocks were analyzed immunohistochemically for expression of tissue inhibin and p53 levels. Inhibin expression was graded by intensity and reactivity, and p53, by its presence or absence. Results. The tumors of 27 patients (57%) stained strongly for inhibin intensity and showed >60% reactivity. Decreased intensity and reactivity of inhibin expression were associated with advanced- stage disease (P = 0.05 and P < 0.01, respectively, by Fisher exact test). Expression of p53 was detected in tumors from 27 patients (57%), and immunoreactivity was associated with compromised progression-free survival (P = 0.016, log-rank test). However, the association between p53 immunoreactivity and disease stage was not significant. Absence of p53 expression was significantly associated with concurrent endometrial carcinoma (P = 0.022), suggesting more molecularly intact tumors that retain functional activity. Conclusions. Although the majority of GCTs show strong expression of inhibin with regard to intensity and reactivity, weak expression is associated with advanced disease but not with decreased progression-free survival. By contrast, expression of p53 is not significantly associated with stage, but increased expression is associated with decreased disease-free survival. Absence of p53 expression appears to be associated with concurrent endometrial carcinoma. (C) 2000 Academic Press.

AB - Objective. The goal of this work was to determine the cellular content of inhibin and p53 in granulosa cell tumors (GCTs). Methods. Clinical records of 47 patients (mean age, 54 years; range, 20-85 years) presenting with GCT surgically managed at our institution were abstracted. International Federation of Gynecology stage I was assigned in 39 patients, stage II in 2, and stage III in 6. Concomitant endometrial carcinoma was identified in 6 patients. Mean follow-up was 13.6 years (range, 1 day to 37.6 years). Sections from paraffin-embedded tissue blocks were analyzed immunohistochemically for expression of tissue inhibin and p53 levels. Inhibin expression was graded by intensity and reactivity, and p53, by its presence or absence. Results. The tumors of 27 patients (57%) stained strongly for inhibin intensity and showed >60% reactivity. Decreased intensity and reactivity of inhibin expression were associated with advanced- stage disease (P = 0.05 and P < 0.01, respectively, by Fisher exact test). Expression of p53 was detected in tumors from 27 patients (57%), and immunoreactivity was associated with compromised progression-free survival (P = 0.016, log-rank test). However, the association between p53 immunoreactivity and disease stage was not significant. Absence of p53 expression was significantly associated with concurrent endometrial carcinoma (P = 0.022), suggesting more molecularly intact tumors that retain functional activity. Conclusions. Although the majority of GCTs show strong expression of inhibin with regard to intensity and reactivity, weak expression is associated with advanced disease but not with decreased progression-free survival. By contrast, expression of p53 is not significantly associated with stage, but increased expression is associated with decreased disease-free survival. Absence of p53 expression appears to be associated with concurrent endometrial carcinoma. (C) 2000 Academic Press.

KW - Cancer stage

KW - Immunohistochemistry

KW - Neoplasm

KW - Prognosis

KW - Retrospective review

UR - http://www.scopus.com/inward/record.url?scp=0034032021&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034032021&partnerID=8YFLogxK

U2 - 10.1006/gyno.2000.5774

DO - 10.1006/gyno.2000.5774

M3 - Article

C2 - 10785470

AN - SCOPUS:0034032021

VL - 77

SP - 232

EP - 236

JO - Gynecologic Oncology

JF - Gynecologic Oncology

SN - 0090-8258

IS - 2

ER -